PMID- 35771390
OWN - NLM
STAT- MEDLINE
DCOM- 20221005
LR  - 20221112
IS  - 0975-0711 (Electronic)
IS  - 0254-8860 (Linking)
VI  - 41
IP  - 4
DP  - 2022 Aug
TI  - Nocturnal acid breakthrough and esophageal acidification during treatment with 
      dexlansoprazole as compared to omeprazole in patients with gastroesophageal 
      reflux disease.
PG  - 405-414
LID - 10.1007/s12664-022-01270-3 [doi]
AB  - BACKGROUND: Nocturnal acid breakthrough (NAB) may differ based on duration of 
      proton pump inhibitor (PPI) action and Helicobacter pylori (H. pylori) infection; 
      NAB may influence esophageal acidification (EA) and mucosal damage. 
      Dexlansoprazole, a long-acting PPI, was not compared with omeprazole for NAB, 
      gastric acid suppression, and EA in relation to H. pylori infection. METHODS: In 
      this prospective open-label comparative observational study, gastroesophageal 
      reflux disease (GERD) patients were evaluated using 24-h dual-channel 
      pH-impedance monitoring while on dexlansoprazole (60 mg, n = 39) and omeprazole 
      (20 mg, n = 41) to study the degree of gastric acid suppression, esophageal acid 
      exposure, and NAB (primary outcome measures). H. pylori was detected by rapid 
      urease test and histology. RESULTS: NAB tended to be frequent with omeprazole 
      than dexlansoprazole (33/41 [80.5%] vs. 23/39 [59%]; p = 0.06). Though nocturnal 
      mean esophageal pH was comparable between the dexlansoprazole and omeprazole 
      groups, its duration was less with the former (181.5 [15.2-334.2] vs. 283 
      [158-366] min, p = 0.03). NAB was as frequent in the H. pylori-infected than the 
      non-infected group (11/19 [57.9%] vs. 45/61 [73.8%]; p = 0.1). The nocturnal 
      gastric and esophageal pH in the H. pylori-infected group was higher than in the 
      non-infected group (4.6 +/- 1.7 vs. 4 +/- 1.6, p = 0.157; 6.1 +/- 0.6 vs. 5.8 +/- 0.6, p 
      = 0.128). Dexlansoprazole tended to increase 24-h and nocturnal mean gastric pH 
      among H. pylori-infected more than omeprazole (5.9 +/- 1.1 vs. 4.2 +/- 1.7, p = 
      0.023; 5.7 +/- 1.2 vs. 3.8 +/- 1.5, p = 0.006). CONCLUSION: Dexlansoprazole is more 
      effective than omeprazole in suppressing gastric acid secretion, resulting in 
      lesser EA and NAB, particularly in the presence of H. pylori.
CI  - (c) 2022. Indian Society of Gastroenterology.
FAU - Ghoshal, Uday C
AU  - Ghoshal UC
AD  - Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical 
      Sciences, Lucknow, 226 014, India. udayghoshal@gmail.com.
FAU - Blaachandran, Arjun
AU  - Blaachandran A
AD  - Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical 
      Sciences, Lucknow, 226 014, India.
FAU - Rai, Sushmita
AU  - Rai S
AD  - Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical 
      Sciences, Lucknow, 226 014, India.
FAU - Misra, Asha
AU  - Misra A
AD  - Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical 
      Sciences, Lucknow, 226 014, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220630
PL  - India
TA  - Indian J Gastroenterol
JT  - Indian journal of gastroenterology : official journal of the Indian Society of 
      Gastroenterology
JID - 8409436
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 3.5.1.5 (Urease)
RN  - KG60484QX9 (Omeprazole)
RN  - UYE4T5I70X (Dexlansoprazole)
SB  - IM
CIN - Indian J Gastroenterol. 2022 Aug;41(4):321-324. PMID: 36087212
MH  - Dexlansoprazole
MH  - *Gastroesophageal Reflux/drug therapy
MH  - *Helicobacter Infections/complications/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Omeprazole
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/pharmacology
MH  - Urease
OTO - NOTNLM
OT  - Ambulatory pH-metry,  Esophageal acid exposure
OT  - Gastric acid
OT  - Gastroesophageal reflux
OT  - Helicobacter pylori
OT  - Impedance monitoring, Proton pump inhibitor
OT  - Sleep disorders
EDAT- 2022/07/01 06:00
MHDA- 2022/10/06 06:00
CRDT- 2022/06/30 11:19
PHST- 2022/02/14 00:00 [received]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/10/06 06:00 [medline]
PHST- 2022/06/30 11:19 [entrez]
AID - 10.1007/s12664-022-01270-3 [pii]
AID - 10.1007/s12664-022-01270-3 [doi]
PST - ppublish
SO  - Indian J Gastroenterol. 2022 Aug;41(4):405-414. doi: 10.1007/s12664-022-01270-3. 
      Epub 2022 Jun 30.